Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human intravenous immunoglobulin therapy

J C Scott-Moncrieff1, W J Reagan

  • 1Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, IN 47907, USA.

Seminars in Veterinary Medicine and Surgery (Small Animal)
|August 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical data, clinicopathologic findings and outcome in dogs with amegakaryocytic thrombocytopenia and primary immune-mediated thrombocytopenia.

The Journal of small animal practice·2016
Same author

Effect of a Limited Iodine Diet on Iodine Uptake by Thyroid Glands in Hyperthyroid Cats.

Journal of veterinary internal medicine·2015
Same author

Effect of Feeding an Iodine-Restricted Diet in Cats with Spontaneous Hyperthyroidism.

Journal of veterinary internal medicine·2015
Same author

Use of the cortisol-to-ACTH ratio for diagnosis of primary hypoadrenocorticism in dogs.

Journal of veterinary internal medicine·2014
Same author

Clinical findings, diagnostic test results, and treatment outcome in cats with spontaneous hyperadrenocorticism: 30 cases.

Journal of veterinary internal medicine·2014
Same author

Diagnosis of spontaneous canine hyperadrenocorticism: 2012 ACVIM consensus statement (small animal).

Journal of veterinary internal medicine·2013

Human intravenous immunoglobulin (hIVIG) effectively treats immune-mediated diseases in dogs, including immune-mediated hemolytic anemia (IMHA). While generally safe, careful monitoring for adverse effects like thromboembolism is crucial during treatment.

Area of Science:

  • Veterinary Medicine
  • Immunology

Background:

  • Human intravenous immunoglobulin (hIVIG) is derived from healthy donor plasma.
  • Initially for primary immunodeficiencies, hIVIG shows efficacy in immune-mediated diseases.

Purpose of the Study:

  • To evaluate the use of hIVIG in treating canine immune-mediated diseases.
  • To determine effective dosages and administration protocols for hIVIG in dogs.

Main Methods:

  • Review of existing studies on hIVIG treatment in dogs.
  • Analysis of hIVIG dosages (0.5-1.5 g/kg) and infusion times (6-12 hours).

Main Results:

  • hIVIG has been used for canine immune-mediated hemolytic anemia (IMHA), immune-mediated thrombocytopenia, and anemia with myelofibrosis.

Related Experiment Videos

  • Short-term hematocrit improvement observed in IMHA dogs; longer-term responses seen in dogs with nonregenerative anemia and myelofibrosis.

    • Conclusions:

    • hIVIG can be a valuable treatment for specific immune-mediated conditions in dogs.
    • Careful monitoring for adverse reactions, including thromboembolism, is essential.
    • Further research is needed to establish the safety of multiple hIVIG treatments.